Clinical factors associated with the efficacy of SASP in refractory-UC patients
| CR | Non-CR | |||
|---|---|---|---|---|
| n=25 | n=11 | p-value | ||
| Gender (M/F) | 19/6 | 8/3 | 1 | |
| Age (year) (Median) | 42 (18-76) | 31 (20-85) | 0.95 | |
| Disease Duration (year) (Median) | 2.0 (0.1-20.3) | 0.3 (0-18.8) | 0.174 | |
| Extent of Disease (%) | Extensive colitis | 13 (52.0) | 8 (72.7) | 0.583 |
| Left-sided | 11 (44.0) | 2 (18.2) | ||
| Proctitis | 1 (4.0) | 1 (9.1) | ||
| Clinical Course (%) | Initial attack type | 3 (12.0) | 5 (45.5) | 0.395 |
| Chronic active type | 10 (40.0) | 3 (27.3) | ||
| Chronic intermittent type | 9 (36.0) | 2 (18.2) | ||
| Acute severe type | 3 (12.0) | 1 (9.1) | ||
| Clinical Activity score (Median) | 6 (5-11) | 9 (5-16) | 0.024 | |
| Endoscopic Mayo score (Median) | 2 (2-3) | 2 (2-3) | 0.628 | |
| CRP (mg/dl) (Median) | 0.42 (0.02-7.56) | 0.89 (0.25-13.44) | 0.012 | |
| SASP (%) | Change to SASP | 15 (60.0) | 10 (90.9) | 0.116 |
| Addition of SASP | 10 (40.0) | 1 (9.1) | ||
| Medication prior to initiating SASP (%) | Corticosteroid | 1 (4.0) | 1 (9.1) | 0.524 |
| Thiopurine | 10 (40.0) | 0 | 0.016 | |
| GMAA | 2 (8.0) | 2 (18.2) | 0.57 | |
| Tacrolimus | 3 (12.0) | 1 (9.1) | 1 | |
| Anti TNF-α agent | 5 (20.0) | 1 (9.1) | 0.643 | |
| History of medication (%) | Corticosteroid | 13 (52.0) | 4 (36.4) | 0.481 |
| Thiopurine | 10 (40.0) | 2 (18.2) | 0.268 | |
| GMAA | 8 (32.0) | 2 (18.2) | 0.688 | |
| Tacrolimus | 6 (24.0%) | 2 (18.2) | 1 | |
| Anti TNF-α agent | 9 (36.0) | 1 (9.1) | 0.127 |
CR, clinical remission; CRP, C-reactive protein; SASP, sulphasalazine; GMAA, Granulocyte monocyte adsorption apheresis'; TNF, tumor necrosis factor.